(Q28200403)

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

ASHP therapeutic position statement on the daily use of aspirin for preventing cardiovascular events

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Low-dose aspirin for the prevention of atherothrombosis

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Warfarin, aspirin, or both after myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

A randomized trial of aspirin to prevent colorectal adenomas

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.03077.X

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Prophylactic aspirin and risk of peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X

Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03077.X